Comorbid HIV and myasthenia gravis: Case report and review of the literature

Journal of Clinical Neuromuscular Disease

Volumn 12, Issue 2, 2010, Pages 80-84

  Knopf, Lisa ^a   Menkes, Daniel L ^a  

^a UNIVERSITY OF CONNECTICUT HEALTH CENTER   (United States)

Author keywords

Coinfection; HAART; HIV; Immunosuppression; Myasthenia gravis

Indexed keywords

ATAZANAVIR; AZATHIOPRINE; CHOLINERGIC RECEPTOR ANTIBODY; EFAVIRENZ PLUS EMTRICITABINE PLUS TENOFOVIR DISOPROXIL; EMTRICITABINE PLUS TENOFOVIR DISOPROXIL; PREDNISONE; PYRIDOSTIGMINE; RITONAVIR;

ADULT; CASE REPORT; CD4 LYMPHOCYTE COUNT; COMBINATION CHEMOTHERAPY; COMORBIDITY; DRUG SUBSTITUTION; DRUG TOLERABILITY; DRUG WITHDRAWAL; FATIGUE; FEMALE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MUSCLE WEAKNESS; MYASTHENIA GRAVIS; PARESTHESIA; PRIORITY JOURNAL; REVIEW; WEAKNESS;

ADULT; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; COMORBIDITY; FEMALE; HIV INFECTIONS; HUMANS; MYASTHENIA GRAVIS;

EID: 78651516720     PISSN: 15220443     EISSN: 15371611     Source Type: Journal    
DOI: 10.1097/CND.0b013e3181fb1be7     Document Type: Review

References (14)

1. Authier JF, Chariot P, Gherardi RK. Skeletal muscle involvement in HIV-infected patients in the era of highly active antiretroviral (HAART) therapy. Muscle Nerve. 2005;32:247-260.
2. Nath A, Kerman RH, Novak IS, et al. Immune studies in human immunodeficiency virus infection with myasthenia gravis: a case report. Neurology. 1990;40:581-583.
3. Smith MC, Pawar R, Carey JT, et al. Effect of corticosteroid therapy on human immunodeficiency virus-associated nephropathy. Am J Med. 1994;97:145-151.
4. Saadat K, Kaminski HJ. Ritonavir-associated myasthenia gravis. Muscle Nerve. 1998;21:681-682.
5. Vittecoq D, Morel C, Eymard B, et al. Recovery from myasthenia gravis of a patient infected with human immunodeficiency virus. Clin Infect Dis. 1992;15:379-380.
6. Chiesa E, Bongiovanni M, Melzi S, et al. Efavirenzcontaining highly active antiretroviral therapy in an HIV-infected patient with myasthenia gravis. AIDS. 2003;17:2544-2555.
7. Strong J, Zochodne DW. Seronegative myasthenia gravis and human immunodeficiency virus infection: response to intravenous gamma globulin and prednisone. Can J Neurol Sci. 1998;25:254-256.
8. Gorthi SP, Shankar S, Johri S, et al. HIV infection with myasthenia gravis. J Assoc Physicians India. 2005;53:995-996.
9. Authier FJ, de Grissac N, Degos JD, et al. Transient myasthenia gravis during HIV infection. Muscle Nerve. 1995;18:914-916.
10. Zandman-Goddard G, Shoenfeld Y. HIV and autoimmunity. Autoimmunity Reviews. 2002;1:329-337.
11. Schuurman HJ, Krone WJ, Broekhuizen R, et al. The thymus in acquired immune deficiency syndrome: comparison with other types of immunodeficiency diseases, and presence of components of human immunodeficiency virus type 1. Am J Pathol. 1989;134:1329-1338.
12. Jaretzki A, Barohn RJ, Ernstoff RM, et al. Myasthenia gravis: recommendations for clinical research standards. Task Force of the Medical Scientific Advisory Board of the Myasthenia Gravis Foundation of America. Neurology. 2000;55:16-23.
13. Cupler EJ, Otero C, Hench K, et al. Acetylcholine receptor antibodies as a marker of treatable fatigue in HIV-1 infected individuals. Muscle Nerve. 1996;19:1186-1188.
14. Sanders DB, Evoli A. Immunosuppressive therapies in myasthenia gravis. Autoimmunity. 2010;43:1-8.